2014-02-24 05:34:03 - PFIZER - MERCK Alliance for Ertugliflozin - Not a Better Partner than Merck - a new market research report on companiesandmarkets.com
Merck-Pfizer deal for SGLT2 inhibitor - Ertugliflozin is positive and we see Merck as an ideal partner. The fixed dose combination of Ertugliflozin and Januvia should allow Ertugliflozin a head start in an otherwise competitive market.
The odds of approval are difficult to predict as we have not seen clinical data as yet, but as such SGLT2 remains a risky class and we will have to wait and watch to see if Ertugliflozin is able to emerge clean of safety issues and pave through the high regulatory hurdles for anti-diabetes drug. We currently do not forecast sales from this franchise.
Click for report details: www.companiesandmarkets.com/Market/Healthcare-and-Medical/Market ..
Browse all Healthcare and Medical Market Research Reports www.companiesandmarkets.com/Market/Healthcare-and-Medical/Market ..
Browse all Healthcare and Medical Company Profile Reports www.companiesandmarkets.com/Market/Healthcare-and-Medical/Compan ..
all Latest Market Research Reports www.companiesandmarkets.com/Market/All/Market-Research?aCode=f3f ..
Companiesandmarkets.com is a leading online business information aggregator with over 300,000 market reports and company profiles available to our clients. Our extensive range of reports are sourced from the leading publishers of business information and provide clients with the widest range of information available. In terms of company profiles, Companiesandmarkets.comâs online database allows clients access to market and corporate information to over 100,000 different companies. We provide clients with a fully indexed database of information where clients can find specific market reports on their niche industry sectors of interest.